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Summary 
Background: The circulatory system diseases are one of biggest health problems which still pose a funda-
mental cause of mortality in developed countries. Among those illnesses important place takes myocardial 
ischemia. Aim: The main purpose of this article is to evaluate hospitalization costs of a patient with acute 
coronary syndrome in health care units conducting diagnostic and surgery (coronarography and PTCA) as 
well as in health centres, where patients are treated exclusively pharmacologically. Methods: There has been 
prepared and used author's individual questionnaire enabling estimation of both fixed and variable trea-
tment costs per patient. In economic analysis there have been used micro-costing principle, defining every 
element of used supplies and calculating unit cost. Results: The analysis has shown that fixed costs of one 
hospitalized patient in a clinic equipped in hemodynamics laboratory are only 33% of all costs. In hospitals 
which did not carry out surgeries, variable costs (e.g. medicines) were respectively lower, whereas fixed 
costs were up to 72% of total treatment costs. A great impact on level of costs had two risk factors: smoking 
tobacco and hypercholesterolemia. Conclusions: Increasing number of carried out angioplasty, raises total 
treatment costs of acute coronary syndrome. Over half of all hospitalization costs of one patient with myo-
cardial ischemia in hospitals not equipped in hemodynamics laboratories determines for fixed costs. 
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1. Introduction 
The cardiovascular system disease is a serious 
health problem which, with regard to its dissemina-
tion and costs being in the centre of attention, has 
intensified medical research in developed countries. 
Shortening of life span by 27% as a result of 
cardiovascular system diseases, where almost half of 
it (13%) refers to myocardial ischemia disease. The 
myocardial ischemia disease is the most frequent 
cause of hospitalization in relation to cardiovascu-
lar system diseases. Figures show that almost one 
million adults living in Poland are diagnosed with 
it. One of the most serious forms of cardiovascular 
system disease is myocardial infarction. Annually 
approximately 100 000 Polish adults are diagnosed, 
and almost 40% of those cases are fatal (1). Myo-
cardial ischemia diseases also cause sudden cardiac 
death, often to people who had no earlier symptoms 
of the illness. In Poland mortality caused by cardio-
vascular system diseases is very high and proves to 
bad health state of the society. The most important 
causes of this situation are: lipid disorders, hyper-
tension, obesity, high level of homocysteine as well 
as diabetes. 
 Myocardial infarction has various defini-
tions depending on its clinical, pathomorphological 
and biochemical features. The death of heart muscle 
cells is caused by long-lasting ischaemia, whose 
typical signs are changes in section ST and T wave, 
as well as myocardial necrosis with typical changes 
of the shape in QRS complex. In most cases, acute 
coronary syndrome is caused by a decrease in 
coronary blood flow. In case of transmural myo-
cardial infarction (with elevation of ST section) it 
most often emerges as a result of clot appearing at 
atheromatous lamina, which, in the past, did not ca-
use critical narrowing of vascular lumen, ischaemia 
nor collateral circulation. (2) Myocardial infarction 
(without persisting elevation of ST section) is main-
ly caused by a clot that does not obliterate vascular 
lumen emerging on instable atheromatous lamina. 
In case of acute coronary syndrome, with regard 
to therapy and costs, its essential part is individual 
risk factor. The most essential are biochemical and 
physiological features, which can be modified, such 
as: hypercholesterolaemia, hypertriglyceridaemia, 
low level of HDL, high arterial blood pressure, 
obesity, diabetes, and high concentration of homo-
cysteine as well as thrombogene factors. Moreover, 
arteriosclerosis favours risk factors connected to 
lifestyle, namely: smoking tobacco, excessive con-
sumption of alcohol as well as low physical activity. 
In Europe, economic impact of cardiovascular sy-
stem diseases is connected with both medical costs 
as well as indirect costs, mostly paid by the society. 
2. Materials and methods
Research carried out at the turn of the year 2007 
and 2008, during 6 months period, had prospective 
and multimember cost study character, to which 
were qualified 176 patients diagnosed with acute 
coronary syndrome. The choice of four units to 
conduct the research was made according to three 
hospital reference levels: clinic – highly specialized 
teaching hospitals - (2 units), regional (1 unit) and 
county (2 units). The study was carried out in two 
Polish regions, of Łódź and Lublin.
Among treated patients, 56 were women and 
120 were men, aged 31 to 96. To calculate the costs, 
three identical questionnaires were created and 
subsequently used in all units. The questionna-
ires included all diagnostic, procedures as well 
as preparations made at every stage of hospital 
treatment. Two questionnaires were related to 
variable costs, the first one regarding health care 
centres that do not carry out invasive surgery, and 
the second for hospitals conducting coronarography 
and primary coronary angioplasty with implant of 
stent and balloon. The third questionnaire on fixed 
costs, identical for all units, contained informati-
on related to costs of workers' salaries (including 
Workers Fund fee, National Insurance and pension 
contributions, accident insurance) as well as other 
remaining fixed costs ( e.g. water and sewage, ener-
gy, fuel, maintenance, taxes, payments, insurance, 
kitchen, laundry, transportation also within the 
department, sterilization, administration, depreci-
ation, dissecting-room, extra services and other1 ) 
1 In category „Other” were included costs of service, cleaning 
detergents, underwear/clothes, maintaining materials and office 
supplies.
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per one patient, including average time needed to 
complete the therapy, which was 7.02 days (as for 
hospitals without hemodynamics laboratory it was 
7.7 days, whereas for cardiac wards of clinical hos-
pital, the average was 6.35 days).  The total cost of 
workers' salary was calculated according to annual 
department’s payments, number of medical staff, 
number of patients treated on each ward during 
one year and number of days spent in hospital by 
one patient, required to complete the therapy. To 
calculate the remaining fixed costs, we included the 
total cost of each ward, the number of patients on 
hospital wards treated while studies were carried 
out and the time needed to finish the hospitalisati-
on, related to medical procedure.
Variable costs of hospitalization questionnaire 
consisted of several parts: 
 » proceeding at casualty (concerning diagnostic and 
treatment),
 » proceeding on hospital ward (concerning diagnostic 
and treatment as well as time after classifying for fi-
brinolystic/thrombolistic treatment and after stating 
hyperglycemia,
 » proceeding on hospital ward (surgical treatment).
On the first page of each questionnaire there 
was an ID-tag and name of the hospital,  patient’s 
PESEL number (personal electronic number for 
identification of Polish citizens), the name of the 
hospital ward where the patient was treated, date of 
birth, gender, as well as information about the place 
from where the patient has been taken to hospital. 
The questionnaire included individual risk factors 
connected to cardiovascular system diseases, such 
as: smoking tobacco, diabetes type 1 and 2, hyper-
cholesterolaemia, obesity, metabolic syndrome, 
hypertension. The part regarding pharmacological 
treatment included information about applied me-
dicines, total dose, method and period of time when 
the medicine was taken, total cost of used amo-
unt of medicine as well as the number of medical 
consultations. For economic analysis the micro-co-
sting principle was applied, where every individual 
element of used supplies was defined and then unit 
cost was calculated. In the part related to surgical 
treatment the calculations were done in a similar 
way: variable costs included costs of coronarograp-
hy (therein: materials consumption, type of used 
materials, company which produced them, unit and 
total cost of used materials) and coronal angioplasty 
with implant of stent and balloon (therein: the phar-
macotherapy before and after the surgery, material 
consumption).
3. Results
After analysing the materials collected during the 
research, the results show that average treatment 
cost for one patient with acute coronary syndro-
me in a hospital equipped with hemodynamics 
laboratory amounts to 1 868 €, where 66% (1 239 €) 
are variable costs and 33% (636€) are fixed costs.  In 
hospitals which did not carry out transcutaneous 
invasive surgery the costs were respectively lower, 
i.e. on average 385€ per patient, where 26% (103€) 
were variable costs and the remaining 72% (282€) 
were fixed costs. Among fixed costs, the largest 
expenses of each health care unit were costs cate-
gorized as other (27% of all fixed costs) which were: 
municipal services, purchase of medical equipment 
and materials for diagnostic, clothes/underwear, 
cleaning detergents, “Health and Safety at Work” as 
well as costs of the workers' salaries with taxes and 
other fees, which amounted to 25% of all fixed costs 
(Chart 2).
In hospitals equipped with hemodynamics 
laboratory, carrying out transcutaneous invasive 
surgery, the highest costs were connected with 
necessity for implant of stent surgery (535€) as well 
as the pharmacotherapy before and after the surgery 
(248€).
Analysing the influence of individual risk factors 
on treatment costs, in case of acute coronary 
syndrome it has been noticed that women patients 
being smokers made no considerable difference 
in expenses of hospitalization. On the other hand, 
when male patients were smokers, this had a 
significant influence on treatment costs. Respecti-
vely these costs were: 610€ per one smoking male 
patient and 465 € per one non-smoking. In case of 
hypercholesterolaemia, the costs of treatment in the 
group with high risk factor as well as without were 
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approximately the same. 
The largest economic difference was among hos-
pitalized women with diabetes type 2. Treatment 
costs for women with diabetes type 2 were consi-
derably higher (874€) than the treatment of acute 
coronary syndrome in the group of women without 
that risk factor. 
The highest costs of basic treatment per one 
hospitalized patient refer to pharmacotherapy on 
hospital ward and diagnostic. The only risk factor 
which increases treatment costs for a patient with 
acute coronary syndrome in hospitals that are not 
equipped with hemodynamics laboratory is diabetes 
type 2 (chart 7).
Conclusions:
 › 1.Annual increase in the number of invasive 
surgery, including coronarography and primary 
coronary vessel angioplasty (chart 3) systematically 
elevates treatment costs of patients with acute 
coronary syndrome in Poland
 › 2.The most essential are high fixed costs in 
hospitals that do not carry out transcutaneous  
surgery, because their costs account for 72% of total 
treatment costs
 › 3.Detailed economic analysis provides the possi-
bility to monitor and compare costs in different 
references' units and to use those data in pharma-
co-economical analyses.
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Chart 1. Acute Coronary Syndrome treatment costs' structure in individual hospital units in Poland per one hospita-
lised patient (in Euro) 
Source: Author’s analysis.
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Chart 2. Fixed treatment costs structure in individual hospital units in Poland per one hospitalised patient (in Euro) 
Source: Author’s analysis.
Chart 3. Number of carried out coronarography and angioplasty in Poland in period of 1999-2005. 
Source: Author’s analysis.
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Table 1. Cost of surgical treatment including all components per one hospitalised patient (in Euro) 
Figures
 Mean (€) N Minimum (€) Maximum (€) Std deviation (€)
mat_stent 535 75 0 1628 421
far_stent 248 75 0 1122 436
mat_kor 135 75 280,5 850 94
mat_bal 58 75 0 696 134
bad_od 54 75 0 583 65
N Ważnych (ob-
servation only)
206 75 976 230
far_bal 45 75 0 1121 221
far_od 41 75 0 149 32
dia_od 33 75 0 162 22
far_kor 10 75 0 747 86,00
mat_od 7 75 0 23,5 5
mat1_stent 3 75 0 145 17
dia_iz 2 75 0 4 2
mat_kor 1,5 75 0 2,7 1,5
kon_od 0,6 75 0 13 3
kon_kor 0,4 75 0 33 4
mat1_bal 0,2 75 0 6 0,7
far_hip 0,16 75 0 6 1
mat_iz 0,06 75 0 0,2 0,05
far_fib 0,05 75 0 4 0,5
mat_fib 0,03 75 0 2,6 0,3
far_iz 0 75 0 0 0
bad_iz 0 75 0 0 0
kon_iz 0 75 0 0 0
dia_hip 0 75 0 0 0
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Gloss:
mat_stent: materials used during angioplasty with implant of stent, far_stent: pharmacotherapy  before 
and after the surgery (the implant of stent), mat_kor: materials used during coronarography, mat_bal: 
materials used during coronary vessel angioplasty with the implant of balloon, bad_od: laboratory analysis 
in hospital, far_bal: pharmacotherapy before and after the surgery (implent of stent), far_od: pharmacothe-
rapy on hospital ward, dia_od: diagnostics on hospital ward, far_kor: pharmacotherapy used over corona-
rography, mat_od: materials used on hospital ward, mat1_stent: materials used during angioplasty with the 
implant of stent, dia_iz: diagnostic at casualty, mat_kor: materials used during coronarography exami-
nation, kon_od: medical consultations carried on hospital ward, kon_kor: medical consultations during 
coronarography, mat1_bal: materials used during balloon's angioplasty, far_hip: pharmacotherapy used in 
case of hyperglycemia, mat_iz: materials used at casualty, far_fib: pharmacotherapy used during fibrino-
lysis, mat_fib: materials used during fibrinolysis, far_iz: pharmacotherapy at casualty, bad_iz: laboratory 
analysis at casualty, kon_iz: specialistic medical consultations at casualty, dia_hip: diagnostics made in case 
of hyperglycemia.    
Chart 4. Treatment cost of one hospitalized patient – including surgery (in Euro) 
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Gloss:
K: average treatment costs of a woman with specific risk factor, K_brak cz_r: average treatment costs of 
a woman without specific risk factor, M: average treatment costs of a man with specific risk factor, M_brak 
cz_r: average treatment costs of a man without specific risk factor, pal: smoking tobacco, hip: hypercholeste-
rolaemia,
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Chart 5. Influence of each risk factor on implant of stent to a patient with acute coronary syndrome (in Euro) 
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Gloss:
mat_iz: materials used at casualty, kon_iz: medical consultations at casualty, far_od: pharmacological 
treatment on hospital ward, bad_od: laboratory analysis on hospital ward, dia_od: diagnostic made on 
hospital ward, mat_od: materials used on hospital ward, kon_od: medical consultations on hospital ward, 
far_fib: pharmacotherapy used during fibrinolysis, mat_fib: materials used during fibrinolysis, mat_hip: 
materials used in case of hyperglycemia. 
Chart 6. Costs of basic treatment including all components per one hospitalised patient (in Euro)
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Gloss:
To valuate the costs, into account were taken costs of pharmacological treatment, diagnostic and mate-
rials used on the hospital ward. rr: arterial hypertension, dm1: diabetes type 1, dm2: diabetes type 2, otyl: 
abdominal obesity, hip:  hypercholesterolaemia
Gloss: 
rr: arterial hypertension, dm1: diabetes type 1, dm2: diabetes type 2, otyl: abdominal obesity, hip: hyper-
cholesterolaemia. 
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Chart 7. Influence of each risk factor on patients' treatment costs on hospital ward in hospitals that do not carry out 
surgery (in Euro)
Chart 8. Risk factors appearing in different groups of patients treated in hospitals that do not carry out surgery. 
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Gloss:
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Gloss:
To valuate the costs, into account were taken costs of pharmacological treatment, diagnostic and mate-
rials used on the hospital ward. rr: arterial hypertension, dm1: diabetes type 1, dm2: diabetes type 2, otyl: 
abdominal obesity, hip:  hypercholesterolaemia
Gloss: 
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Chart 7. Influence of each risk factor on patients' treatment costs on hospital ward in hospitals that do not carry out 
surgery (in Euro)
Chart 8. Risk factors appearing in different groups of patients treated in hospitals that do not carry out surgery. 
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